( fter the welfare of the patients and di...)Alchemia Reports Preliminary Positive Efficacy Data From HyCAMP,Phase II Trial,Health

    ENQUIRIES: Dr. Tracie Ramsdale

    Chief Executive Officer

    Alchemia Limited

    Tel: +61-7-3340-0200


    RELEASED BY:

    Ms Anna Whybird

    Phillips Group

    Tel: +61-7-3230-5000

About HyACT

HyACT(TM) is a proprietary delivery technology which utilises Hyaluronic acid (HA), to deliver and enhance the retention of anti-cancer drugs within tumours. The drug becomes entrapped in a matrix of HA which binds to HA receptors located on the tumour resulting in more of the drug being delivered to the tumour cells. In preclinical studies, the HyACT(TM) technology has demonstrated improved delivery of the drug to the tumour resulting in significantly reduced toxicity and increased efficacy and survival.

About Irinotecan

Irinotecan is widely used in the treatment of metastatic colorectal cancer, and is being evaluated in many other tumour types. Like most cytotoxics the use of irinotecan is restricted by its side effects, the most significant of which are diarrhoea and neutropenia, and limited activity in some patients. Sales of Pfizer's irinotecan (Camptosar(R) ) were US$903 million in 2006, and patent exclusivity for the drug expires in 2008 in the US and 2009 in the EU.

About HyCAMP(TM)

HyCAMP(TM) is a proprietary formulation of the anti-cancer drug irinotecan. Preclinical studies with HyCAMP(TM) demonstrated improved delivery of the drug to the tumour, resulting in increased efficacy and reduced toxicity. The phase II clinical trial was initiated to evaluate HyCAMP(TM) in patients with metastatic colorectal cancer.

CLINICAL APPENDIX

The following additional information is provided in accordance with the Code of Best Practice for ASX Reporting by Life Science Companies

    Trial Title        Randomised Phase II Trial of irinotecan with Hyaluronic

                       Acid (HyCAMP(T
'"/>




Page: 1 2 3 4 5 6 7 
Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology
With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal
Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III
Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with
CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for
Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018
Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose
Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical
Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of
Once-Per-Month Hematide for the Treatment of Anemia